Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.
Oct 7, 2016Seattle Genetics and Agensys, an Affiliate of Astellas, Highlight Enfortumab Vedotin (ASG-22ME) and ASG-15ME Phase 1 Data in Metastatic Urothelial Cancer at 2016 ESMO Congress-Objective Response Rates Presented for Both Antibody-Drug Conjugate Programs- -Enfortumab Vedotin Demonstrates 59 Percent Objective Response Rate at Recommended Phase 2 Dose of 1.25 mg/kg, Supporting Advancement of the Development Program-
- Sep 28, 2016Astellas ranked for its commitment and support of working mothers
- Sep 12, 2016Astellas Oncology Selects Five C3 Prize™ Finalists to Pitch Ideas for Changing Cancer Care to Panel Including Robert Herjavec at Stanford Medicine XOut of more than 100 applicants from all over the world, five health care advocates with bright ideas to change cancer care will compete for a chance to win one of three grants totaling $100,000
- Aug 16, 2016For the second consecutive year, the pharmaceutical company was named to the 2016 Great Place to Work® ranking among medium-sized multinational businesses in the country